Showing 3761-3770 of 5773 results for "".
- Phase 3 Clinical Study IND Accepted in China for Alimera’s Fluocinolone Acetonide Intravitreal Implanthttps://modernod.com/news/phase-3-clinical-study-ind-accepted-in-china-for-alimeras-fluocinolone-acetonide-intravitreal-implant/2480901/Alimera Sciences announced that its partner, Ocumension Therapeutics, received approval from the National Medical Products Administration for its IND application to begin the phase 3 clinical study for fluocinolone acetonide intravitreal implant in support of a filing for marketing approval
- Rayner Acquires Stake in Sustainable Surgical Instrument Belgian Manufacturer Hasa Optixhttps://modernod.com/news/rayner-acquires-stake-in-sustainable-surgical-instrument-belgian-manufacturer-hasa-optix/2480900/Rayner announced that it has entered into a commercial partnership and concurrently acquired a stake in Hasa Optix, a Brussels-based manufacturer of single use ophthalmic surgical instruments and instrument sets. The investment closed June 7, 2022. Financial terms of the deal
- Staar Surgical Celebrates 2 Million Lens Milestone for Implantable Collamer Lens (ICL)https://modernod.com/news/staar-surgical-celebrates-2-million-lens-milestone-for-implantable-collamer-lens-icl/2480897/Staar Surgical announced that more than 2 million Visian Implantable Collamer lenses (ICLs) have been sold globally, including more than one and a half million of the company’s latest generation of implantable lenses–EVO Visian ICLs (EVO). New to the U.S. market, E
- Alcon Partners with Football Player Cooper Kupp to Promote Pataday for Eye Allergieshttps://modernod.com/news/alcon-partners-with-football-player-cooper-kupp-to-promote-pataday-for-eye-allergies/2480895/Alcon announced a partnership with Cooper Kupp, professional football wide receiver, to share his experience with eye allergies and help other eye allergy sufferers find relief with Pataday Once Daily Relief Extra Strength. 
- Nicox Now Expects Topline Results from NCX 470 Mont Blanc Phase 3 Glaucoma Trial in November 2022https://modernod.com/news/nicox-now-expects-topline-results-from-ncx-470-mont-blanc-phase-3-glaucoma-trial-in-november-2022/2480892/Nicox SA announced that it has closed screening for additional patients in its phase 3 Mont Blanc clinical trial of NCX 470 0.1% in patients with open-angle glaucoma or ocular hypertension. Therefore, the company now expects
- Novartis Receives FDA Approval of Beovu for the Treatment of Diabetic Macular Edemahttps://modernod.com/news/novartis-announces-fda-approval-of-beovu-for-the-treatment-of-diabetic-macular-edema/2480891/Novartis announced that the FDA has approved Beovu (brolucizumab-dbll) 6 mg for the treatment of diabetic macular edema (DME). Today’s approval represents the second FDA-approved indication for Beovu, which was first approved for the treatment of wet age-related macular degeneration in
- Apellis Submits New Drug Application to the FDA for Pegcetacoplan for Geographic Atrophyhttps://modernod.com/news/apellis-announces-submission-of-nda-to-the-fda-for-pegcetacoplan-for-geographic-atrophy/2480890/Apellis Pharmaceuticals announced that the company has submitted a new drug application (NDA) to the FDA for intravitreal pegcetacoplan, an investigational, targeted C3 therapy, for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)
- Newly Published 12-Month Clinical Data for Sight Sciences’ Omni Surgical Systemhttps://modernod.com/news/newly-published-12-month-clinical-data-for-sight-sciences-omni-surgical-system/2480887/Sight Sciences announced publication in
- Submissions Now Being Accepted for Innovation Stage Speakers and Content for Vision Expo West 2022https://modernod.com/news/submissions-now-being-accepted-for-innovation-stage-speakers-and-content-for-vision-expo-west-2022/2480883/The Vision Council and RX, co-organizers of Vision Expo, announced that submissions are being accepted for Innovation Stage speakers, presentations and panels for
- Dopavision Appoints Mark S. Wuttke, PhD, as Chief Executive Officerhttps://modernod.com/news/dopavision-appoints-mark-s-wuttke-phd-as-chief-executive-officer/2480881/Dopavision announced that Mark S. Wuttke, PhD, has been appointed as the company´s Chief Executive Officer. He succeeds Dopavision´s co-founder and previous Managing Director Stefan Zundel, who will remain on Dopavision´s advisory board and continue to advise the company.</